Sporadic early-onset Alzheimer’s disease (sEOAD) is often associated with atypical clinical features, yet the cause of this heterogeneity remains unclear. This study investigated post-mortem atrophy of the locus coeruleus (LC) in sEOAD and late-onset Alzheimer’s disease (LOAD). Levels of LC atrophy, as estimated by pathologist-rating of hypopigmentation, were compared between sEOAD (n = 115) and LOAD (n = 672) participants while controlling for other measures of pathological progression. Subsequent analyses compared low vs. high LC atrophy sEOAD subgroups on neuropsychological test performance. Results show nearly 4 times greater likelihood of higher LC atrophy in sEOAD as compared to LOAD (p < .005). sEOAD participants with greater LC atrophy displayed significantly worse performance on various baseline measures of attentional functioning (p < .05), despite similar global cognition (p = .25). These findings suggest the LC is an important potential driver of clinical and pathological heterogeneity in sEOAD.
MurrayMEGraff-RadfordNRRossOAPetersenRCDuaraRDicksonDW. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785–796.
2.
van der FlierWMPijnenburgYAFoxNCScheltensP. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol. 2011;10(3):280–288.
3.
BarnesJDickersonBCFrostCJiskootLCWolkDvan der FlierWM. Alzheimer’s disease first symptoms are age dependent: evidence from the NACC dataset. Alzheimer’s Dement. 2015;11(11):1349–1357.
4.
BoltonCLoweJKutnarKLaneCPyykkonenB. Neuropsychological differentiation of early-onset and late-onset Alzheimer’s disease in autopsy-confirmed cases. Clin Neuropsychol. 2018;32(4):585.
5.
BoltonCPyykkonenB. The relation of age and APOE genotype to clinical heterogeneity in early onset Alzheimer’s disease. Alzheimer’s Dement. 2019;15(7):449.
6.
DickersonBCBrickhouseMMcGinnisSWolkDA. Alzheimer’s disease: the influence of age on clinical heterogeneity through the human brain connectome. Alzheimers Dement Diagn Assess Dis Monit. 2016;6:122–135.
7.
JoubertSGourNGuedjE, et al.Early-onset and late-onset Alzheimer’s disease are associated with distinct patterns of memory impairment. Cortex. 2016;74(Supplement C):217–232. doi:10.1016/j.cortex.2015.10.014
8.
KoedamELGELaufferVVan der VliesAEVan der FlierWMScheltensPPijnenburgYAL. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401–1408.
9.
PalasíAGutiérrez-IglesiasBAlegretM, et al.Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold?J Neurol. 2015;262(5):1238–1246.
10.
SmitsLLPijnenburgYALvan der VliesAE, et al.Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. Eur Neuropsychopharmacol. 2015;25(7):1010–1017.
11.
MendezMFLeeASJoshiAShapiraJS. Nonamnestic presentations of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(6):413–420.
12.
FrisoniGBPievaniMTestaC, et al.The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain. 2007;130(3):720–730.
13.
KarasGScheltensPRomboutsS, et al.Precuneus atrophy in early-onset Alzheimer’s disease: a morphometric structural MRI study. Neuroradiology. 2007;49(12):967–976.
14.
MöllerCVrenkenHJiskootL, et al.Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiol Aging. 2013;34(8):2014–2022.
15.
VerclytteSLopesRLenfantP, et al.Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG-PET in early-onset Alzheimer’s disease. J Neuroimaging. 2016;26(2):207–212.
16.
BraakHThalDRGhebremedhinEDel TrediciK. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960–969.
17.
ZarowCLynessSAMortimerJAChuiHC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60(3):337. doi:10.1001/archneur.60.3.337
18.
Aston-JonesGCohenJD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:40–450.
19.
CoullJTBüchelCFristonKJFrithCD. Noradrenergically mediated plasticity in a human attentional neuronal network. NeuroImage. 1999;10(6):705–715.
20.
MurphyPRRobertsonIHBalstersJHO’connellRG. Pupillometry and P3 index the locus coeruleus-noradrenergic arousal function in humans. Psychophysiology. 2011;48(11):1532–1543.
21.
SaraSJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10(3):211–223.
22.
MoretCBrileyM. The importance of norepinephrine in depression. Neuropsychiatr Dis Treat. 2011;7(suppl 1):9–13.
23.
JacobsDSanoMMarderK, et al.Age at onset of Alzheimer’s disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 1994;44(7):1215–1220.
24.
BallariniTIaccarinoLMagnaniG, et al.Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer’s disease. Hum Brain Mapp. 2016;37(12):4234–4247.
25.
HymanBTTrojanowskiJQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the national institute on aging and the Reagan institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56(10):1095–1097. doi:10.1097/00005072-199710000-00002
26.
HymanBTPhelpsCHBeachTG, et al.National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13. doi:10.1016/j.jalz.2011.10.007
27.
EllisonDLoveSChimelliL, et al.Parkinsonism and akinetic–rigid disorders. In: Neuropathology. 3rd ed. Elsevier; 2013, 567–585.
28.
WeintraubSSalmonDMercaldoN, et al.The Alzheimer’s disease centers’ uniform data set (UDS): the neuropsychological test battery. Alzheimer Dis Assoc Disord. 2009;23(2):91–101.
29.
ShirkSDMitchellMBShaughnessyLW, et al.A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. Alzheimers Res Ther. 2011;3(6):32.
30.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12(3):189–198.
31.
WechslerD. Wechsler Memory Scale-Revised Manual. The Psychological Corporation; 1987.
ReitanRM. Trail Making Test: Manual for Administration and Scoring. Reitan Neuropsychology Laboratory; 1992.
34.
KaplanEGoodglassHWeintraubS. The Boston Naming Test. Philadelphia: Lea & Febiger; 1983.
35.
HelmstaedterCWietzkeJLutzMT. Unique and shared validity of the “Wechsler logical memory test,” the “California verbal learning test,” and the “verbal learning and memory test” in patients with epilepsy. Epilepsy Res. 2009;87(2-3):203–212. doi:10.1016/j.eplepsyres.2009.09.002
36.
AdriaanseSMBinnewijzendMAAOssenkoppeleR, et al.Widespread disruption of functional brain organization in early-onset Alzheimer’s disease. PLoS One. 2014;9(7):e102995.
GourNFelicianODidicM, et al.Functional connectivity changes differ in early and late-onset Alzheimer’s disease. Hum Brain Mapp. 2014;35(7):2978–2994.
39.
SatohAIijimaKM. Roles of tau pathology in the Locus Coeruleus (LC) in age-associated pathophysiology and Alzheimer’s disease pathogenesis: potential strategies to protect the LC against aging. Brain Res. 2019;1702:17–28.
40.
VliesAEvan derKoedamELGEPijnenburgYa LTwiskJWRScheltensPFlierWMvan der. Most rapid cognitive decline in APOE ε4 negative Alzheimer’s disease with early onset. Psychol Med. 2009;39(11):1907–1911.
41.
WilsonRSNagSBoylePA, et al.Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology. 2013;80(13):1202–1208.
42.
ChalermpalanupapTWeinshenkerDRorabaughJM. Down but not out: the consequences of pretangle tau in the locus coeruleus [Internet]. Neural Plast. 2017. Accessed April 1, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605916/
43.
CallahanPMPlagenhoefMRBlakeDTTerryAV. Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys. Neuropharmacology. 2019;155:65–75.
44.
NiHCShangCYGauSSLinYJHuangHCYangLK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2013;16(9):1959–1973.
45.
MohsRCShiovitzTMTariotPNPorsteinssonAPBakerKDFeldmanPD. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-Month, randomized, double-blind, placebo-controlled, parallel-trial study. Am J Geriatr Psychiatry. 2009;17(9):752–759.
46.
FeinsteinDLKalininSBraunD. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. J Neurochem. 2016;139(S2):154–178.
47.
JacobsHILRiphagenJMRamakersIHGBVerheyFRJ. Alzheimer’s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Mol Psychiatry. 2019;26(3):897–906.
48.
ChalermpalanupapTKinkeadBHuWT, et al.Targeting norepinephrine in mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther. 2013;5(2):21.
BettsMJKirilinaEOtaduyMCG, et al.Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019;142(9):2558–2571. doi:10.1093/brain/awz193
51.
DahlMJMatherMDüzelS, et al.Higher rostral locus coeruleus integrity is associated with better memory performance in older adults. Nat Hum Behav2019;3(11):1203–1214doi:10.1038/s41562-019-0715-2
